OSIVAX - OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.

PIID: 75A50125C00006

Signed Date: Feb 2, 2026Effective Date: Sep 30, 2025End Date: Closes in 154 days

Award $

$744K

Vendor

OSIVAX

NAICS

541714

Signed Date

Feb 2, 2026

Key Details

Dollars Obligated

$743,969.31

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

Office of Assistant Secretary for Preparedness and Response

NAICS Code

541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Product Service Code

AN14 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; R&D ADMINISTRATIVE EXPENSES

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Description

OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.

Context & Analysis

On Feb 2, 2026, Department of Health and Human Services obligated $743,969.31 to OSIVAX for oxivax - aoi #28: influenza vaccine innovation. advancing metagenomic next-generation sequencing based agnostic diagnostics for viral pathogens the overall objective of this contract is to prepare the…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. The contract is scheduled through Mar 31, 2027 — approximately 5 months remaining.